Summary

Osteogenesis imperfecta is a heritable disorder that causes bone fragility. Mutations in type I collagen result in autosomal dominant osteogenesis imperfecta, whereas mutations in either of two components of the collagen prolyl 3-hydroxylation complex (cartilage-associated protein [CRTAP] and prolyl 3-hydroxylase 1 [P3H1]) cause autosomal recessive osteogenesis imperfecta with rhizomelia (shortening of proximal segments of upper and lower limbs) and delayed collagen folding. We identified two siblings who had recessive osteogenesis imperfecta without rhizomelia. They had a homozygous start-codon mutation in the peptidyl-prolyl isomerase B gene (PPIB), which results in a lack of cyclophilin B (CyPB), the third component of the complex. The proband’s collagen had normal collagen folding and normal prolyl 3-hydroxylation, suggesting that CyPB is not the exclusive peptidyl-prolyl cis–trans isomerase that catalyzes the rate-limiting step in collagen folding, as is currently thought.
CRTAP causes severe or lethal autosomal recessive osteogenesis imperfecta, which accounts for 5 to 7% of all severe cases of osteogenesis imperfecta. 3

Null mutations of CRTAP or LEPRE1 cause severe osteogenesis imperfecta with rhizomelia, 8–13 classified, respectively, as type VII (Online Mendelian Inheritance in Man [OMIM] number, 610682) and type VIII (OMIM number 610915). These mutations lead to a deficiency of these two components of the complex and a reduction in or absence of α1(1)Pro986 hydroxylation. Unexpectedly, a lack of the complex causes collagen overmodification by P4H and LH. We hypothesized that the delay in helical folding is due to the unavailability of the complex to shuttle CyPB to the carboxyl end of the helix, rather than to the absence of the 3-hydroxylation modification itself. CyPB, a ubiquitous peptidyl-prolyl cis-trans isomerase (PPlase), is currently thought to catalyze the prolyl isomerization that is the rate-limiting step in collagen folding. 14,15

We describe here two siblings who had autosomal recessive osteogenesis imperfecta due to a homozygous mutation in the start codon of PPIB. The lack of CyPB results in moderate osteogenesis imperfecta without rhizomelia, associated with normal α1(1)Pro986 hydroxylation and normal modification of the collagen helix. Our findings suggest that CyPB is not the unique rate-limiting PPlase for type I collagen folding in vivo.

**CASE REPORTS**

The patients were siblings with moderately severe osteogenesis imperfecta who were born to consanguineous Senegalese parents residing in New York City (Fig. 1A). Both children had white sclerae and normal dentition. They did not have rhizomelia or severe deformity of the long bones, and their skin was normal in appearance and extensibility. Although they had moderate axial growth deficiency, their hand length and segmental proportions were appropriate for their age. Gross motor development was moderately delayed, owing to low muscle tone and weakness, but both children had attained ambulation. Results of hearing and vision tests, and echocardiographic assessment were normal. Their intellectual development was normal (see the Supplementary Appendix). No bone samples were obtained during orthopedic procedures.

The proband (Patient III-4) was a 4-year-old girl who was delivered at term by cesarean section owing to the breech position. She weighed 2720 g (6 lb) (10th percentile) at birth and had a wide anterior fontanelle; bilateral fractures of the humeri, radii, ulnae, femora, and tibiae were noted on radiographs. She was able to sit independently at the age of 2.75 years and was able to walk at the age of 3.5 years with the use of long leg braces and a walker. Postnatal fractures began to occur when she reached 6 months of age; she sustained six long-bone fractures and underwent four lower-extremity osteotomy procedures. Her growth curve fell below normal by the age of 6 months. At 28 months of age, her weight and length were both at the 50th percentile for a normal 9-month-old girl. She had generalized, moderate ligamentous laxity, triangular facies with a high-bossed forehead, and proptosis. An umbilical hernia was noted at the age of 5 months. She had bilateral pes planus. Skeletal radiographs obtained when she was a newborn revealed osteoporotic long bones, with undertubulation and bowing of the femora and tibiae (Fig. 1B, top row). By the age of 15 months, the vertebral bodies of T11 through L2 showed substantial anterior compression. At 33 months, long-bone undertubulation had improved but was still present in the femoral metaphyses. The z score for L1 to L4 on dual-energy x-ray absorptiometry (DXA) was −3.9 at the age of 3.5 years.

The proband’s sibling (Patient III-1) was a 12-year-old boy who also had sickle cell disease, although he had had no sickle cell crises that required hospitalization. Despite this coexisting disease, his osteogenesis imperfecta was milder than that of the proband. He was the product of a term pregnancy and weighed 2268 g (5 lb) at birth (<5th percentile). His first fracture occurred at the age of 3 months, after which he had more than eight long-bone fractures of the lower extremities and underwent four osteotomy procedures. Spontaneous ambulation did not occur until 2 years of age. His growth was moderately delayed; at the age of 12.3 years, his height and weight were the same as those of an average 8-year-old. He had a head circumference of 49 cm at 11 years of age (25th percentile). He was hospitalized with pneumonia at age 11. The physical examination was notable for generalized, moderate ligamentous laxity, proptosis, a prominent sagittal suture, a flattened occiput, a narrow thorax, and bilateral pes planus. Skeletal radiographs showed generalized osteopenia but not rhizomelia (Fig. 1B, bot-
The long bones had thin cortices and normal diaphyseal modeling; the femoral metaphyses were mildly undertubulated. The vertebrae were not compressed (Fig. 1 in the Supplementary Appendix). When he was 11 years old, the z score on DXA of L1 to L4 was −1.3.

**METHODS**

**GENETIC ANALYSIS**

We screened genomic DNA (gDNA) of dermal fibroblasts, leukocytes, or both from the proband and her affected brother, as well as gDNA from
their parents and unaffected siblings. Sequencing of complementary DNA and genomic DNA (gDNA) from the proband revealed no mutations in COL1A1, COL1A2, CRTAP, or LEPRE1.

The five exons and flanking intronic sequences of PPBP gDNA from the proband were sequenced, and the PPBP mutation was confirmed by restriction-enzyme digestion. This mutation was not found in DNA samples from 115 healthy West African subjects (230 chromosomes) or in multiple single-nucleotide-polymorphism (SNP) databases. The expression levels of PPBP, CRTAP, and LEPRE1 in fibroblasts, which share a mesodermal origin with osteoblasts, were examined by means of a real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messenger RNA expression (Assays-on-Demand, Applied Biosystems).

**IN VITRO BIOCHEMICAL TESTS**

The details of collagen biochemical assessments in dermal fibroblasts are provided in the Supplementary Appendix. Western blots of cell lysates were probed with antibodies to CyPB (Abcam), CRTAP, or P3H1 (Abnova) and were scanned on a LI-COR Odyssey machine. Amino acid chromatography and electrospray mass spectrometry were performed.⁹

**IMMUNOFLOURESCENCE MICROSCOPY**

Cells from the proband and a 5-year-old control subject were stained with antibodies to CyPB (Abcam), CRTAP, glucose-regulated protein 94 (GRP94) (Abcam), or protein disulfide isomerase (PDI) (Stressgen). Secondary antibodies conjugated to fluorophores of different wavelengths were used to examine protein colocalization by means of confocal microscopy.

**RESULTS**

**IDENTIFICATION OF THE PPBP MUTATION**

The proband and her affected sibling were homozygous for a c.2T→G mutation in PPBP (Fig. 1C). Homozygosity for the mutation in affected children and heterozygosity in parents and unaffected siblings were confirmed by the elimination of an NaiIlII restriction site (Fig. 1D). This mutation results in substitution of an arginine for the methionine start codon (Met1).¹⁶ This alteration is expected to eliminate the initiation of translation.

**PPBP EXPRESSION AND PPBP IN FIBROBLASTS**

PPBP transcripts in the proband were about 55% of the normal level on the basis of real-time RT-PCR assay (Table 1) and were unaffected by the use of emetine to inhibit nonsense-mediated decay. CyPB protein was undetectable in the proband fibroblast lysate (Fig. 2A) and concentrated media (data not shown) on Western blotting with the use of three different antibodies; no CyPB staining was present on immunofluorescence (Fig. 2B). PPBP transcript levels were normal, and CyPB protein levels were moderately reduced in fibroblasts obtained from the proband’s father (Fig. 2A and Table 1).

**EFFECT OF LACK OF CYPB ON THE PROLYL 3-HYDROXYLASE COMPLEX AND COLLAGEN FOLDING**

In cells that were homozygous and those that were heterozygous for the PPBP mutation, CRTAP and LEPRE1 transcript levels were moderately elevated as compared with levels in the control cells (Table 1). Interestingly, Western blotting showed that CRTAP and P3H1 protein levels in the proband were about half the normal levels (Fig. 2A); these decreases were confirmed on immunofluorescence microscopy (Fig. 2C and 2D and Table 1). The proband’s father had normal levels of CRTAP and P3H1 proteins.

The homozygous PPBP mutation did not affect type I collagen modification and folding. Tandem mass spectrometry revealed normal 3-hydroxylation of 98% of α1(I) pro-986 residues (Table 1, and Fig. 2A in the Supplementary Appendix). Furthermore, collagen helical modification appeared to be normal in homozygous mutant cells, since tandem mass spectrometry showed that prolyl 4-hydroxylation and lysyl hydroxylation of specific tryptic peptides from α1(I) and α2(I) chains was in the normal range, and amino acid chromatography yielded normal proportions of hydroxylated lysine residues (Table 1). Gel electrophoresis of collagen from the proband showed near-normal width and baseline of the alpha-chain bands (Fig. 2E), and collagen thermal stability was normal (Fig. 2B in the Supplementary Appendix).

**DISCUSSION**

We identified two siblings with moderately severe, autosomal recessive osteogenesis imperfecta caused by a homozygous start-codon mutation in PPBP, the gene that encodes CyPB.¹⁶ Osteogenesis imperfecta
caused by the absence of CyPB is much milder than the severe or lethal osteogenesis imperfecta caused by a deficiency of P3H1 or CRTAP,8-13 although all three of these proteins comprise the prolyl 3-hydroxylation complex in the endoplasmic reticulum.7,8 Unexpectedly, type I collagen folding is not delayed by the absence of CyPB, as it is with P3H1 or CRTAP deficiency.8-10 This finding provides an important insight into collagen peptidyl-prolyl isomerization in vivo.

The two siblings had a novel PPIB mutation. A missense PPIB mutation (Gly31Arg) has been reported in horses in association with a degenerative skin disease17; the equine skeletal phenotype and collagen biochemical features were not reported. The patients described here had normal results on skin examination. Patients who lack CyPB, a condition that we propose to designate as type IX osteogenesis imperfecta, have low bone mass and multiple long-bone fractures, requiring osteotomy and placement of intramedullary rods, but attain ambulation. A lack of CyPB does not cause the rhizomelia or extreme growth delay that is found when P3H1 or CRTAP is absent, nor does it result in the abnormalities of the growth plate11,18 that are seen in cases of severe autosomal dominant or recessive osteogenesis imperfecta. The osteoporosis in type IX osteogenesis imperfecta is much less severe than that in types VII and VIII (DXA z scores of −1.3 and −3.9 in type IX vs. average DXA z scores of −6 to −7 in types VII and VIII), although extremely short stature in types VII and VIII also contributes to a very low z score on DXA. Both siblings had white sclerae and normal dentition, which are also found in patients with P3H1 or CRTAP deficiency. Their hand length was proportionate for their age, as is seen in P3H1 deficiency,10 but without the metacarpal shortening. The differences in the severity of skeletal dysplasia and relative stature between our two patients may in part reflect homozygosity for other genes due to parental consanguinity.

The distinctions between the phenotype of CyPB absence and the phenotype of P3H1 or CRTAP deficiency correlate with two important biochemical differences in type I collagen. In the absence of P3H1 or CRTAP, α1(I)Pro986 3-hydroxylation is decreased and collagen folding is delayed,

<table>
<thead>
<tr>
<th>Variable</th>
<th>Proband</th>
<th>Father</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA expression†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPIB</td>
<td>0.56±0.10</td>
<td>1.04±0.08</td>
<td>—</td>
</tr>
<tr>
<td>CRTAP</td>
<td>1.44±0.19</td>
<td>1.42±0.22</td>
<td>—</td>
</tr>
<tr>
<td>LEPRE1</td>
<td>1.82±0.21</td>
<td>1.80±0.34</td>
<td>—</td>
</tr>
<tr>
<td>Protein‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CyPB</td>
<td>&lt;0.01</td>
<td>0.61±0.25</td>
<td>—</td>
</tr>
<tr>
<td>CRTAP</td>
<td>0.63±0.12</td>
<td>1.13±0.21</td>
<td>—</td>
</tr>
<tr>
<td>P3H1</td>
<td>0.34±0.10</td>
<td>1.29±0.11</td>
<td>—</td>
</tr>
<tr>
<td>Hydroxylation (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lysine residues in type I collagen modified by LH§</td>
<td>19.7</td>
<td>—</td>
<td>17.7–22.0</td>
</tr>
<tr>
<td>α1(I)Pro986 residues with 3-hydroxylation¶</td>
<td>98</td>
<td>—</td>
<td>94–97</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. CRTAP denotes cartilage-associated protein, CyPB cyclophilin B, LEPRE1 leucine- and proline-enriched proteoglycan 1, LH lysyl hydroxylase, mRNA messenger RNA, P3H1 prolyl 3-hydroxylase 1, and PPIB the gene encoding peptidyl-prolyl isomerase B.
† The relative expression of each mRNA was normalized to glyceraldehyde-3-phosphate dehydrogenase expression and then compared with the relative mRNA expression of a control fibroblast cell line (which was arbitrarily set to 1). These tests were performed in triplicate on three separate samples.
‡ The level of each protein was normalized to actin levels and then compared with normalized protein levels from a control fibroblast cell line (which was arbitrarily set to 1). This test was performed on three samples.
§ The percentage of hydroxylated lysine residues of type I collagen was determined by high-performance liquid chromatography.
¶ The percentage of α1(I)Pro986 that underwent 3-hydroxylation was determined by mass spectrometry of tryptic peptides.
Figure 2. Effects of the PP1B Mutation on Components of the Prolyl 3-Hydroxylation Complex and Type I Collagen Modification.

Western blots of fibroblast CyPB, CRTAP, and P3H1 in the proband (III-4) and her father (II-3), compared with actin antibody–loading controls, are shown in Panel A. The lack of CyPB protein and decreases in CRTAP and P3H1 in the proband corroborate the results of immunofluorescence staining. Immunofluorescence staining of fibroblasts from the proband and from a control subject, colocalized with endoplasmic reticulum marker PDI or GRP94, are shown for the three components of the prolyl 3-hydroxylation complex — cyclophilin B (CyPB) in Panel B, cartilage-associated protein (CRTAP) in Panel C, and prolyl 3-hydroxylase 1 (P3H1) in Panel D. The cells from the proband show no signal for CyPB, with a decrease in staining of both CRTAP and P3H1. Panel E shows the steady-state type I collagen protein in fibroblasts from the proband and from a control subject. Migration of the alpha chains (α1[Ⅴ], α1[Ⅰ], and α2[Ⅰ]) in the cell layer is normal in the proband, and the α1(Ⅰ) collagen band is minimally broadened.
resulting in overmodification of the helical lysine and proline residues. In contrast, the lack of CyPB is associated with normal levels of α1(I)Pro986 3-hydroxylation and helical proline 4-hydroxylation and lysine hydroxylation.

The cyclophilins are a family of ubiquitous intracellular proteins that differ in their subcellular location and their binding affinity for the immunosuppressive drug cyclosporine. All isoforms possess peptidyl-prolyl cis–trans isomerase activity, converting the cis conformation of prolines to the trans conformation necessary for proper folding. cis–trans isomerization is the rate-limiting step in the folding of the collagen helix, which contains approximately 20% proline residues. CyPB, the cyclophilin that resides in the endoplasmic reticulum, has been shown to isomerize prolyl bonds for type III collagen in vitro. Chick fibroblasts treated with cyclosporine exhibit delayed collagen folding with excess hydroxylation of helical proline and lysine residues; this finding suggests, but does not prove, that CyPB is the major isomerase for collagen folding, since cyclosporine inhibits multiple proteins.

We hypothesized that one role of the prolyl 3-hydroxylation complex may be to position CyPB at the carboxyl end of the collagen helix, where folding is initiated. Recently, the complex has been shown in vitro to have both chaperone and PPIase activity; the PPIase activity is almost entirely due to CyPB and can be inhibited by cyclosporine. The mutation in our patients resulted in a lack of CyPB and a partial secondary reduction in the P3H1–CRTAP complex. However, sufficient complex remained for the normal 3-hydroxylation of α1(I)Pro986 residues. In this situation, the normal folding of type I collagen strongly suggests that CyPB is not the major type I collagen–folding isomerase or that redundancy exists for this function. The milder skeletal phenotype of our patients as compared with patients who have type VII or VIII osteogenesis imperfecta, may reflect the presence of Pro986 hydroxylation and proper collagen folding, as well as partial availability of P3H1 and CRTAP for their matrix functions. The loss of other functions of CyPB, including collagen transport in the intracellular secretory pathway, might also contribute to the phenotype.

These unexpected data open fundamental questions concerning the function of the 3-hydroxylation modification, the role of CyPB in the complex, and the identity of the major collagen isomerase. It is tempting to speculate that FKBP65, another PPIase that resides in the endoplasmic reticulum and binds to collagen, may be the major isomerase or that FKBP65 and CyPB have redundant functions. FKBP65 is partially inhibited by both cyclosporine and FK506, both of which delay collagen folding. To date, all probands with normal type I collagen folding have an intact P3H1–CRTAP complex and normal α1(I)Pro986 hydroxylation. Perhaps 3-hydroxylation triggers a conformational change of the collagen substrate or 3-hydroxylation complex that facilitates binding of FKBP65.

**REFERENCES**

Copyright © 2010 Massachusetts Medical Society.